Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial

JAMA Otolaryngol Head Neck Surg. 2023 Sep 1;149(9):847-849. doi: 10.1001/jamaoto.2023.1729.
No abstract available

Plain language summary

This secondary analysis of a phase 2 clinical trial examines long-term survival for resectable cutaneous squamous cell carcinoma of the head and neck according to pathologic response.

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Carcinoma, Squamous Cell* / drug therapy
  • Carcinoma, Squamous Cell* / pathology
  • Carcinoma, Squamous Cell* / surgery
  • Head and Neck Neoplasms* / drug therapy
  • Head and Neck Neoplasms* / surgery
  • Humans
  • Neoadjuvant Therapy
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology
  • Skin Neoplasms* / surgery
  • Squamous Cell Carcinoma of Head and Neck / drug therapy
  • Treatment Outcome

Substances

  • cemiplimab